Perinatal Depression Screening, Diagnosis, and Treatment Guideline

Changes as of April 2021

Target Population

Integrated Mental Health/Maternal Mental Health

Screening and Diagnosis

Treatment

Overview of options

Shared decision-making: pregnant women

Key points: breastfeeding women

Pharmacologic options

Follow-up

Evidence Summary

References

Guideline Development Process and Team

Last guideline approval: April 2021

Guidelines are systematically developed statements to assist patients and providers in choosing appropriate health care for specific clinical conditions. While guidelines are useful aids to assist providers in determining appropriate practices for many patients with specific clinical problems or prevention issues, guidelines are not meant to replace the clinical judgment of the individual provider or establish a standard of care. The recommendations contained in the guidelines may not be appropriate for use in all circumstances. The inclusion of a recommendation in a guideline does not imply coverage. A decision to adopt any particular recommendation must be made by the provider in light of the circumstances presented by the individual patient.
Changes as of April 2021

This updated 2021 guideline has only minor differences from the previous (2019) version. The evidence review identified no newly published high-quality studies that would change our current recommendations.

Target Population

The recommendations in this guideline apply to

- Pregnant women.
- Postpartum women from childbirth through the first year of the baby’s life.
- Women who are already taking antidepressant medications and are considering becoming pregnant.

Integrated Mental Health/Maternal Mental Health

Kaiser Permanente Washington has integrated mental health into all primary care clinics. The goal of Integrated Mental Health is to create a welcoming environment for patients to address common problems—alcohol and substance use disorders as well as depression—with their primary care teams. A major element has been transitioning primary care social workers to a new role of integrated mental health specialist, in which they work as “provider extenders” to address patient needs without disrupting patient flow and team cycle time. Social workers offer consultation to providers, brief interventions, and short-term (4–6 visits) counseling for individuals with mild to moderate depression and alcohol or substance use disorders.

Maternal Mental Health (MMH) Screening is part of the initiative that focuses on pregnant and postpartum women through an infant’s first year of life. Recent research demonstrates that pregnancy and the first year of the infant’s life pose increased risks to the mother’s mental health and well-being, including depression, anxiety, and domestic violence. MMH screening tools and processes are similar to those used in Integrated Mental Health, but they are tailored for maternal health and include questions about domestic violence.
Screening and Diagnosis

Routine screening using the Maternal Mental Health (MMH) Screening questionnaire is recommended for all pregnant and postpartum women. MMH screening is optimally performed at four visits during the pregnancy and four times through the infant’s first year, at the following routine visits:

<table>
<thead>
<tr>
<th>Pregnancy care (In Women’s Health or Family Practice)</th>
<th>Pediatric care (In Pediatrics or Family Practice)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• First prenatal visit</td>
<td>• 7–14-day well baby visit</td>
</tr>
<tr>
<td>• 16-week visit</td>
<td>• 4-month well baby visit</td>
</tr>
<tr>
<td>• 32-week visit</td>
<td>• 6-month well baby visit</td>
</tr>
<tr>
<td>• Postpartum</td>
<td>• 12-month well baby visit</td>
</tr>
</tbody>
</table>

MMH screening has been integrated into the OB and Well Child Visit SmartSets. The MMH incorporates the Patient Health Questionnaire (PHQ-9), the Generalized Anxiety Disorder (GAD-2) questionnaire, and questions about substance abuse and domestic violence. A job aid (staff intranet) provides details about MMH visit content and documentation.

**Note:** Pregnant and postpartum women who have a current diagnosis of depression—whether made prior to pregnancy or during the perinatal period—should be followed with the Maternal Mental Health Screening questionnaire at the same set of routine visits.

**Severity assessment**

The first nine questions on the MMH questionnaire comprise the PHQ-9. The PHQ-9 score is the sum of these responses.

Depression severity is correlated with PHQ-9 scores as follows:

- 20–27: Severe major depression
- 15–19: Moderately severe major depression
- 10–14: Moderate major depression
- 5–9: Indeterminate or mild depression. People with this score could have had major depression that is now improved, chronic mild depression (dysthymia), or transient mild depression. The PHQ-9 cannot distinguish among these. Use clinical judgment to determine appropriate next steps.

**Screening for suicidal ideation**

Suicidal ideation is assessed by question 9 on the PHQ-9.

Over the past 2 weeks, how often have you been bothered by any of the following problems: thoughts that you would be better off dead, or hurting yourself in some way?

If the patient scores 2 or 3 on this PHQ-9 question (or otherwise expresses suicidal thoughts, exhibits suicidal behaviors, or has suicide risk factors), administer the Suicide Risk Assessment (SRA). (Also available as a KP HealthConnect Flowsheet.)

The SRA is scored by adding the “yes” answers together.

- 6: Acute risk for suicide
- 3–5: Moderate risk
- 0–2: Low risk

**SRA score of 3 or higher**

Requires completion of a crisis response plan and lethal means removal. Use .LOCK2LIVE to direct patients to a web-based decision aid to help individuals at risk of suicide make decisions about lethal means safety, particularly firearms and prescription medications.

While the patient is still in the room, obtain immediate consultation with a mental health professional through:
• Warm patient hand-off to clinic social worker/integrated mental health specialist, or
• Mind Phone

**SRA score of 0–2**
Arrange a follow-up appointment with Mental Health through:
• KP HealthConnect order Urgent referral to Mental Health, or
• Warm patient hand-off to integrated mental health specialist

**Psychiatric comorbidities and other life stressors**

The remaining questions on the Maternal Mental Health Screen (questions 10–21) are designed to assess for other mental health conditions and life stressors. Consider consultation or referral to Mental Health for more definitive diagnosis and management if any of these factors are present.

<p>| Table 1. Mental health conditions or life stressors to consider in pregnant and postpartum women |
|---------------------------------|-------------------------------------------------|------------------------------------------------|</p>
<table>
<thead>
<tr>
<th>Mental health condition or life stressor</th>
<th>MMH screening question</th>
<th>Next steps</th>
</tr>
</thead>
</table>
| Anxiety disorders, including generalized anxiety disorder, obsessive-compulsive disorder, and panic disorder | **GAD-2**
Over the last 2 weeks, how often have you been bothered by the following problems?
• MMH #10: Feeling nervous, anxious, or on edge
• MMH #11: Not being able to stop or control worrying | If score of 3 or higher, follow with the GAD-7. (Available in KP HealthConnect.) |
| Alcohol misuse | **AUDIT-C**
• MMH #13: How often did you have a drink containing alcohol in the last 3 months?
• MBH #14: How many drinks containing alcohol did you have on a typical day when you were drinking in the last 3 months?
• MMH #15: How often did you have 4 or more drinks on one occasion in the last 3 months? | See the Adult Unhealthy Drinking Guideline. |
| Marijuana misuse | • MMH #16: In the last 3 months, have you used marijuana? | If daily or almost daily, use the Substance Use Symptom Checklist in KP HealthConnect. |
| Drug misuse | • MMH #17: In the last 3 months, have you used an illegal drug or used a prescription medication for non-medical reasons? | If yes, use the Substance Use Symptom Checklist in KP HealthConnect. |
| Abuse/violence | • MMH #19: Are you currently in a relationship where your partner hits, slaps, kicks, or hurts you?
• MMH #20: Does your partner control where you go or make you feel afraid?
• MMH #21: Have you had a partner who physically hurt or threatened you? | If yes, follow up with open-ended, non-leading questions to encourage self-disclosure. Consider referral to Social Work. |
Treatment: Overview of Options

Treatment recommendations are based on the patient's PHQ-9 score and may include psychotherapy, antidepressants, or both. On average, antidepressant medication and psychotherapy have similar effectiveness. Supportive care is recommended for all patients receiving care for depression.

The goals of treatment are to achieve complete remission and prevent relapse or recurrence of depression. Remission is defined as a PHQ-9 score of < 5.

### 20–27: Severe major depression
For patients with severe major depression, **combined antidepressant medication and psychotherapy** is the preferred treatment recommendation. Antidepressant medication alone is an alternative recommendation. Psychotherapy alone is not recommended for these patients.

### Moderately severe (15–19) and moderate (10–14) major depression
For patients with moderately severe or moderate major depression, **shared decision-making** around treatment options—antidepressants, psychotherapy, and combination therapy—is recommended. For patients with moderately severe depression (PHQ-9 score of 15–19), combining psychotherapy and antidepressants may be more effective than using either treatment alone.

### 5–9: Indeterminate or mild depression
For patients with indeterminate or mild depression, treatment with antidepressants or psychotherapy is usually not recommended. Supportive care, including patient education and emotional support and guidance, is recommended.

#### Supportive care
Support and education in the primary care setting are critical and contribute to the likelihood of good follow-through on treatment. Supportive care is recommended for all patients receiving care for depression.

Patient education should include:
- The cause, symptoms and natural history of major depression
- Shared decision-making about treatment options
- Information on what to expect during treatment
- Follow-up (office visits, e-mail, and/or telephone)

In addition to patient education, supportive care includes emotional support and guidance. Providers can engage in behavioral activation by encouraging patients to consider and adopt some self-management responsibilities, such as writing in a journal or reading self-help books, scheduling pleasant activities, spending time with people who support them, and engaging in physical activity. Patients who are receiving supportive care but are not prescribed medications should be encouraged to follow up with a member of their clinical team within 2–4 weeks of diagnosis, as early behavioral activation may improve patients' self-efficacy and continued investment in treatment (Cuijpers 2014). If possible, schedule follow-up at the time of diagnosis.

#### Psychotherapy
Psychotherapy often involves a series of structured sessions in which a provider helps the patient identify and change behaviors (isolation, inactivity, avoidance of problem-solving) and cognitions (negative rumination, magnification of bad news, minimization of good news). Mental Health offers therapy for major depression and other severe persistent mental illness (SPMI). Social workers are available in every primary care clinic to
offer brief interventions and short-term counseling (4–6 weeks), which is better suited to patients with mild to moderate depression (PHQ-9 score 5–14).

Group therapy is an alternative or adjunct to individual therapy. Patients may be referred to group therapy to learn skills and to lessen isolation. Depression and anxiety (DAG) groups are currently offered in 11 primary care clinics and will be expanding to additional clinics in the coming months. Emotional regulation groups are also being offered in several clinics.

Online cognitive behavioral therapy (CBT) may be an attractive option as access to in-person psychotherapy may be a significant barrier to care.

Combination therapy
For some patients, particularly those with severe depression (PHQ-9 score of 15 or higher), combining psychotherapy and antidepressants may be more effective than using either treatment alone.

Antidepressants
Pregnant and postpartum women considering antidepressants need to be informed of the risks and benefits of pharmacologic treatment through a shared decision-making process.

SSRIs have the most data for use during pregnancy and lactation. Assessing the benefits and risks of taking an antidepressant during pregnancy and lactation is challenging because the evidence is limited to observational studies that are subject to confounding and bias. The potential risks of medication exposure must be balanced with the potential harms of untreated maternal depression. The benefits of breastfeeding seem to outweigh the potential side effects of SSRIs.

Untreated maternal depression has been associated with miscarriage, increased preterm birth, low birth weight, increased rates of cigarette, alcohol and other substance misuse, and poor prenatal care. In the postpartum period there is a greater risk of disturbance in the development of the maternal-infant bond in severely depressed mothers; in addition, postpartum depression has been associated with lower IQ, slower language development, increased risk of ADHD and an increased risk of psychiatric illness in the child.
Shared Decision-Making: Treating Depression in PREGNANT Women

Assessing the benefits and risks of taking an antidepressant during pregnancy and lactation is challenging because the evidence is limited to observational studies that are subject to confounding and bias. There are no good studies about the long-term effects of SSRI exposure in pregnancy. Only small, less rigorous studies are available and seem to indicate no effect on the child’s behavioral, language, or IQ development.

Table 2. Shared decision-making: treating depression with SSRIs DURING PREGNANCY

<table>
<thead>
<tr>
<th>Treatment with SSRIs</th>
<th>No treatment with SSRIs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Advantages</strong></td>
<td></td>
</tr>
<tr>
<td>• Decreased risk of depression relapse (26%)</td>
<td></td>
</tr>
<tr>
<td>• Decreased risk of low birth weight and postnatal complications</td>
<td></td>
</tr>
<tr>
<td>• Similar risk of birth defects as for women who don’t take SSRIs during pregnancy (about 3–5%)</td>
<td></td>
</tr>
<tr>
<td>• No exposure of baby to SSRIs</td>
<td></td>
</tr>
<tr>
<td><strong>Risks to mother</strong></td>
<td></td>
</tr>
<tr>
<td>• Depending on which SSRI is used, increased risk of GI distress, weight gain, insomnia, or sexual issues</td>
<td>High risk of depression relapse (68%)</td>
</tr>
<tr>
<td>• High risk of cigarette, alcohol, and other substance misuse</td>
<td></td>
</tr>
<tr>
<td>• Decreased social support and poor prenatal care</td>
<td></td>
</tr>
<tr>
<td><strong>Risks to baby</strong></td>
<td></td>
</tr>
<tr>
<td>• Increased risk of preterm birth</td>
<td>Increased risk of postnatal complications</td>
</tr>
<tr>
<td>• Withdrawal symptoms at birth in up to 30% of babies, including jitteriness or irritability, tremors, or trouble feeding</td>
<td>Increased risk of crying and difficulty being consoled</td>
</tr>
<tr>
<td>• Increased risk of congenital malformations during the first trimester, especially with fluoxetine and paroxetine</td>
<td>If depression occurs postpartum: increased risk of lower IQ, slower language development, ADHD, psychiatric illness, and suicidal behavior</td>
</tr>
<tr>
<td>• Small risk (&lt;1%) of developing persistent pulmonary hypertension, which may require care in specialty care nursing</td>
<td></td>
</tr>
</tbody>
</table>

Key Points: Treating Depression in BREASTFEEDING Women

- The benefits of breastfeeding generally seem to outweigh the potential side effects of SSRIs.
- In severely depressed postpartum women, the risks of taking SSRIs are generally considered lower than the risk of disturbing the development of the maternal-infant bond.
- Infant drug exposure is generally higher through placental passage than through breast milk. Thus, if a woman has taken an antidepressant during pregnancy, it generally makes sense to continue with the same antidepressant during breastfeeding to minimize the number of medications the infant is exposed to.
- There is weak evidence (e.g., from case studies) linking antidepressant use in breastfeeding mothers with mild adverse events in infants, but because the reported adverse effects were nonspecific (e.g., irritability, sedation, and "colic"), it is unclear whether they were directly related to the medication exposure.
- The risk of drug accumulation and associated toxicity may be higher in premature infants or in infants with signs of compromised hepatic metabolism.
- To minimize the risk to the baby, use the minimum medication dose that provides adequate control of the mother’s symptoms.
- There does not appear to be any benefit to altering the timing of nursing, or selectively discarding portions of the breast milk, to minimize the drug exposure to the baby.
Pharmacologic Options for Pregnant and Breastfeeding Women

In a patient who is not currently receiving drug therapy, sertraline is the drug of first choice because literature supports its use during preconception, throughout pregnancy, and during breastfeeding. However, if the patient previously failed an adequate dose and duration or experienced intolerable side effects on the first-line option, then any of the medications where literature supports use (green-shaded areas of Table 3 on the following page) are reasonable alternatives. Paroxetine is associated with an increased risk of congenital malformations when taken in the first trimester and is therefore contraindicated during pregnancy. Fluoxetine is third-line due to an increased risk of major birth defects when taken during early pregnancy.

In a patient who is on well-established, effective therapy, it is reasonable to continue any of the medications where literature supports use (green-shaded areas) or where absolute risks are likely small (yellow-shaded areas), as the benefits of continuing therapy likely outweigh the risks of switching. However, consideration should be given to switching therapy if the patient is taking a medication for which there is possible evidence of harm (red-shaded areas).

For patient-specific consultations, refer to Mental Health or OB/GYN, or call the Mind Phone.
Table 3. Summary of antidepressant use prior to conception and during pregnancy and lactation

<table>
<thead>
<tr>
<th></th>
<th>Preconception</th>
<th>1st trimester</th>
<th>3rd trimester</th>
<th>Postpartum &amp; lactation</th>
<th>Estimated percentage of maternal dose to baby via breast milk</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sertraline</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.4%–2.3%</td>
</tr>
<tr>
<td>Sertraline is a preferred SSRI during pregnancy and lactation because of its short half-life and the relatively low drug levels found in cord blood and breast milk. For women stable on fluoxetine or citalopram during pregnancy, the possible benefits of switching to sertraline for breastfeeding must be balanced against the possible disruption of switching medication.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Escitalopram</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.9%–7.9%</td>
</tr>
<tr>
<td>Based on limited data, escitalopram appears to be preferable to citalopram during pregnancy and breastfeeding and is considered second-line. Escitalopram shows lower drug levels in breast milk and a general lack of adverse reactions in breastfed infants.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Citalopram</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.7%–9.0%</td>
</tr>
<tr>
<td>Citalopram is excreted into human breast milk. Compared with other SSRI antidepressants, the relative dose to the infant from citalopram was comparable to fluoxetine but higher than that for sertraline and paroxetine. If citalopram is required by the mother, it is not a reason to discontinue breastfeeding.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Paroxetine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.1%–4.3%</td>
</tr>
<tr>
<td>Paroxetine is contraindicated in early pregnancy due to the risk of congenital malformations. Paroxetine has low drug levels in breast milk and is a reasonable option if the drug is started after the 2nd trimester or in the postpartum period.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fluoxetine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.2%–12.0%</td>
</tr>
<tr>
<td>Recent data shows a statistically significant increased relative risk of major birth defects when fluoxetine is taken in early pregnancy, but the absolute risks are small. However, it is still reasonable to switch if the patient would like to minimize the risks. Also, the average amount of drug in breast milk is higher with fluoxetine than with most other SSRIs, and the long-acting, active metabolite norfluoxetine is detectable in the serum of most breastfed infants during the first 2 months postpartum and in a few thereafter. Adverse effects such as colic, fussiness, and drowsiness have been reported in some breastfed infants.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Venlafaxine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.5%–8.1%</td>
</tr>
<tr>
<td><strong>Bupropion</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.2%–2.0%</td>
</tr>
<tr>
<td><strong>Venlafaxine and bupropion</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>While data is limited and evidence for use of these medications during pregnancy and lactation is less clear than for other antidepressants, it is reasonable to consider continuing their use in women who are responding to them. The American Academy of Pediatrics classifies bupropion and venlafaxine as drugs whose effect on the nursing infant is unknown but may be of concern.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 See reference list for Table 3 on page 12.
2 Estimates are weight-adjusted and include the agent and its active metabolites.
Table 4. Recommended antidepressant dosing for PREGNANT OR BREASTFEEDING WOMEN
For women starting or continuing antidepressants during or after pregnancy, use SmartPhrases
.AVSPREGDEPRESSIONMEDSTART
.AVSPREGDEPRESSIONMEDCONT
.AVSDEPRESSIONBREASTFEEDING
.AVSPREGDEPRESSIONPOSTPARTUM
.AVSDEPMATERNALCAREPLAN

<table>
<thead>
<tr>
<th>Line</th>
<th>Medication</th>
<th>Initial dose</th>
<th>Titration schedule</th>
<th>Usual therapeutic dose range</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
<td>Sertraline</td>
<td>50 mg daily x 7 days, then increase to 100 mg daily.</td>
<td>Increase by 50 mg increments at 4-week intervals.</td>
<td>50–200 mg</td>
</tr>
<tr>
<td>2nd</td>
<td>Escitalopram</td>
<td>5 mg daily x 7 days, then increase to 10 mg daily.</td>
<td>Increase to 20 mg daily.</td>
<td>10–20 mg</td>
</tr>
</tbody>
</table>

Other treatment options

**Herbal supplements**

The safety and efficacy of herbal supplements for depression treatment in pregnant and breastfeeding women was not evaluated, as few animal or human studies have been conducted. Due to the lack of evidence and uncertainty in product quality, women who are pregnant, contemplating pregnancy, or lactating should generally be discouraged from using herbal treatments.

**Bright light therapy**

Moderate evidence suggests that the use of bright light therapy is not effective for perinatal depression.

**Follow-up**

See the KPWA Adult and Adolescent Depression Guideline for follow-up recommendations. The Mental Health Monitoring Tool should be used at every follow-up visit for depression after the baby’s first birthday. The SmartPhrase .SMDEPFOLLOWUP may be used when scheduling follow-up visits.
Evidence Summary

This guideline was developed using an evidence-based process, including systematic literature search, critical appraisal, and evidence synthesis.

1. What is the effectiveness and safety of antidepressants in pregnant women with major depressive disorder?

- Pharmacological treatment versus non-pharmacological treatment: The review identified one meta-analysis (van Ravesteyn 2017) and two randomized trials (Forsell 2017, Van Ravesteyn 2018) that compared non-pharmacological treatment versus usual care, psycho-education, or counseling. No pharmacological trials were identified, and harms were not assessed. Although the evidence shows that non-pharmacological treatment might be more effective in reducing depressive symptoms, there is a lack of direct evidence to evaluate the comparative effectiveness and safety of pharmacological and non-pharmacological treatment during pregnancy and the postpartum period.

- Antidepressants for preventing postnatal depression: There is insufficient evidence for or against the use of antidepressants to prevent postnatal depression.

- Untreated depression
  - Treated versus untreated major depression in pregnancy: One systematic review without meta-analysis (Mitchell 2018) was identified. No differences or comparable findings between antidepressant-treated women and untreated women were reported in terms of risk of low birth weight and related outcomes, or gestational lengths. Evidence regarding spontaneous abortion, however, is insufficient to draw conclusions.
  - Untreated depression versus no depression in pregnancy: Compared with pregnant women without depression, moderate evidence shows that the risks of preterm birth (< 37 weeks) and low birth weight (< 2500 g) are significantly higher in pregnant women with untreated depression. Concerning maternal risks of untreated depression, observational studies show that untreated maternal depression is associated with harms to the mother and her offspring (conclusion of 2017 KPWA guideline evidence review).
  - The question on untreated depression was revised in 2021. A systematic review (Fitton 2020) of 16 cohort studies compared antidepressant-treated pregnant women versus untreated depressed women. The authors reported an association between antidepressants and elevated risk of preterm birth and lower gestational age.
  - Considering all the studies, low- to moderate-quality evidence suggests that:
    - Compared with untreated depression, exposure to antidepressants (mostly SSRIs) during pregnancy is associated with increased risk of preterm birth.
    - Untreated depression is also associated with higher risk of preterm birth in comparison with pregnant women without depression.
  - The findings are mixed regarding the effects of untreated depression irrespective of comparison.

- Safety of antidepressants during pregnancy: The 2017 KPWA guideline evidence review concluded that antidepressant use during pregnancy is associated with maternal and fetal risks. In the current review, six meta-analyses assessed the risk of autism. Low evidence shows a significant association between antidepressant exposure during pregnancy and the risk of autism spectrum disease. In addition, fluoxetine is associated with congenital malformations (major malformations, cardiovascular malformations, septal defects, and non-septal defects).

2. What is the effectiveness of bright light therapy in patients aged 12 years and over with major depressive disorder?

   Four meta-analyses (Al-Karawi 2016, Chiu 2017, van Ravesteyn 2017, Holvast 2017) were considered for the review. Patients with depression or postpartum depression and pregnant women with major depressive disorder were included. Some studies included patients who received antidepressants. Treatment lasted up to 8 weeks. Comparators consisted of dim light therapy, red
yellow light, placebo light exposure (250 lux), dim red light (< 5 lux), and usual indoor light (150–200 lux).

Bright light therapy (BLT) alone was significantly effective in reducing depression symptoms. No evidence of efficacy was found for BLT as an adjunct to antidepressants. BLT was not effective during pregnancy or in perinatal depression. Both high-intensity and low-intensity BLT are effective; however, in one meta-analysis, high-intensity BLT was found to be significantly more effective than low-intensity BLT (Chiu 2017). The strength of the evidence is moderate. Moderate evidence supports the use of bright light therapy alone in patients with major depressive disorder.

References in Evidence Summary


References in Table 3


Massachusetts General Hospital Center for Women’s Mental Health: Breastfeeding & Psychiatric Medications. Available from https://womensmentalhealth.org/specialty-clinics/breastfeeding-and-psychiatric-medication/


Guideline Development Process and Team

Development process
The guideline team developed the Perinatal Depression Guideline using an evidence-based process, including systematic literature search, critical appraisal, and evidence synthesis. For details, see Evidence Summary and References.

This edition of the guideline was approved for publication by the Guideline Oversight Group in April 2021.

Team
The Adult & Adolescent Depression Guideline development team included representatives from the following specialties: adolescent medicine, family medicine, family medicine with OB, mental health and wellness, nursing operations, pharmacy, and residency.

Clinician lead: Angie Sparks, MD, Medical Director, Clinical Knowledge Development & Support
Guideline coordinator: Avra Cohen, MN, RN, Clinical Improvement & Prevention
Said Adjao, MD, MPH, Clinical Epidemiologist, Clinical Improvement & Prevention
Lanre Adekola, MD, Residency
Jenny Chan, PharmD, Clinical Pharmacy Services
Barbara Freidman, RN, Nursing Professional Practice and Development
Annelise Gaaserud, MD, MPH, Family Medicine w/ OB
Samantha Jimenez, PsyD, Psychologist, Mental Health and Wellness
Megan Kavanagh, Patient Engagement Team, Clinical Improvement & Prevention
Kimberly Knight, MPH, RN, Clinical Quality Consultant
Robyn Mayfield, Patient Engagement Team, Clinical Improvement & Prevention
Rebecca Parrish, MSW, LCISW, Integrated Mental Health Clinical Consultant & Social Work Manager
Ashok Shimojikrishnan, MD, Child and Adolescent Psychiatrist
Stanley Shyn, MD, Psychiatrist, Depression Quality Champion, Mental Health and Wellness
Ann Stedronsky, Clinical Publications, Clinical Improvement & Prevention
Gina Sucato, MD, MPH, Adolescent Medicine
Jeffrey Vannice, PhD, Psychologist, Mental Health and Wellness